ArticlePediatric blood & cancer2019
Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group.
Article in Pediatric blood & cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and risk factors of distant metastasis among Chinese osteosarcoma patients: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2026Pooled it
- Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review.British journal of cancer · 2025Pooled it
- Paediatric therapeutic development workshop on osteosarcoma.British journal of cancer · 2026Review
- Article
- Prognostic factors and survival outcomes in patients undergoing limb-sparing surgery for primary malignant bone tumors.Frontiers in oncology · 2026Article
- CXCL10-induced chemotaxis ofMolecular therapy. Oncology · 2025Article
- Therapeutic potential of no-ozone cold plasma-activated saline in osteosarcoma through mitochondrial and MAPK pathway modulation.Scientific reports · 2025Article
- Alginate-based biomaterials in orthopedics: What are the prospects for bacterial alginate?World journal of orthopedics · 2025Review
- Correlation Between MRI Characteristic of Osteosarcoma with 2-Year Survival Outcomes.Diagnostics (Basel, Switzerland) · 2025Article
- Prognostic factors for disease progression of central high-grade conventional osteosarcoma of the appendicular skeleton: Single-centre experience within South Africa with minimum 3-year follow-up.Journal of orthopaedics · 2025Article
- Robust statistical assessment of Oncogenotype to Organotropism translation in xenografted zebrafish.bioRxiv : the preprint server for biology · 2025Article
- Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group report.Journal of the National Cancer Institute · 2024Article
- CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives.EJC paediatric oncology · 2024Article
- A bifunctional bortezomib-loaded porous nano-hydroxyapatite/alginate scaffold for simultaneous tumor inhibition and bone regeneration.Journal of nanobiotechnology · 2023Article
- Preclinical evaluation of Raman spectroscopy for pedicular screw insertion surgical guidance in a porcine spine model.Journal of biomedical optics · 2023Article
- Attenuation of Endoplasmic Reticulum Stress Enhances Carvacrol-Induced Apoptosis in Osteosarcoma Cell Lines.Life (Basel, Switzerland) · 2023Article
- Controlled-release of apatinib for targeted inhibition of osteosarcoma by supramolecular nanovalve-modified mesoporous silica.Frontiers in bioengineering and biotechnology · 2023Article
- Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy.Scientific reports · 2022Article
- MicroRNA-886 suppresses osteosarcoma cell proliferation and its maturation is suppressed by long non-coding RNA OXCT1-AS1.Bioengineered · 2022Article
- The SIRT1-HMGB1 axis: Therapeutic potential to ameliorate inflammatory responses and tumor occurrence.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDespite drastic improvement in overall survival for pediatric patients with cancer, those with osteosarcoma have stable rates of survival since the 1980s. This project evaluates the effect of several variables on survival after first recurrence in patients with osteosarcoma.
methodsData from three prospective North American cooperative group trials for newly diagnosed osteosarcoma are included: INT-0133, POG-9754, and AOST0121. The analytic population for this study is all enrolled patients with first event-free survival (EFS) event of relapse. The primary outcome measure for this retrospective analysis was survival after recurrence (SAR).
resultsThe analytic population consisted of N = 431 patients. SAR was statistically significantly associated with age at enrollment (<10 years, P = 0.027), presence of metastatic disease at diagnosis (localized, P < 0.0001), site of relapse (combination lung + bone, unfavorable, P = 0.005), and time to first relapse (2+ years, favorable, P < 0.0001) in multivariate analysis. Ethnicity, primary site of tumor, race, and sex were not significantly related to SAR.
conclusionsProlonged SAR in patients with relapsed osteosarcoma is associated with age, extent of disease at diagnosis, site of and time to relapse. Adolescent and young adult patients with osteosarcoma have shorter SAR than younger patients, consistent with studies showing decreased overall survival in this group. Although patients with primary metastatic disease have shorter SAR, there is a subset of patients who relapse greater than 2 years from initial diagnosis that will become survivors. Histological response was significantly associated with time to relapse, but was not predictive of SAR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.